Results 51 to 60 of about 22,830 (226)

Growth Differentiation Factor 15 as a Cerebrospinal Fluid Biomarker for the Diagnosis and Prognosis of Leptomeningeal Metastasis

Annals of Neurology, EarlyView.
Objective As leptomeningeal metastasis (LM) has a poor prognosis, reliable cerebrospinal fluid (CSF) diagnostic biomarkers are urgently needed. This study evaluated the diagnostic value of CSF growth differentiation factor 15 (GDF15) in LM from lung adenocarcinoma (LUAD) and breast cancer (BC).
Haoyu Ruan, Jie Li, Fuhai Wang, Lei Zhang, Jie Luo, Yuan Mu, Ting Wang, Yuqing Wu, Jingping Liu, Yunyun Ning, Xuan Deng, Ming Guan, Jian Xu   +12 more
wiley   +1 more source

Co-constructing methodology as a power shift dynamic: insights from a community-based research project on lung cancer treatment side effects

Methods in Psychology
This article examines the co-construction of research methodology as a dynamic space for redistributing power between different forms of knowledge in a community-based study on cognitive and psychiatric side effects of targeted therapies for ALK/ROS1 ...
Myriam Pannard, Maïssa Fadhlaoui, Céline Chanial, Pierre Nicot, Guillaume Becker, Marie Pailhe, Sandrine Alliaume, Sophie Seror, Evelyne Pauchet, Joël Pauchet, Fabien Pichat, Rita Bogdani, Valérie Montagny, Virginie Desestret, Michaël Duruisseaux   +14 more
doaj   +1 more source

ZBED6 Knockout Promotes Skeletal Muscle Development in Bama Pigs by Relieving Transcriptional Repression of CDKN1A

Animal Research and One Health, EarlyView.
Integrated transcriptomic and functional analyses identify CDKN1A as a direct target of ZBED6 in Bama pigs. ZBED6 knockout relieves transcriptional repression of CDKN1A, thereby promoting myogenic differentiation and skeletal muscle development.
Yitian Ma, Xiu Lin, Pengtao Yuan, Yabin Pu, Yuehui Ma, Zixiao Jiang, Lin Jiang, Chongyang Li, Dandan Wang   +8 more
wiley   +1 more source

Ros1 binds to the ros1 promoter region.

, 2016
(A) The graph generated with the CLC Genomics Workbench 7.5 software (CLC bio) shows the ChIP-seq read distribution in the genomic region containing ros1 in output DNA from the sample where maize was infected with FB1Δros1-Ros1HA x FB2Δros1-Ros1HA ...
Marie Tollot (599617), Janine Altmüller (120887), Regine Kahmann (180257), Christian Becker (49615), Julien Y. Dutheil (109041), Carl-Eric Wegner (2849981), Daniela Assmann (2849978)   +6 more
core   +1 more source

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Thoracic Cancer, 2022
Background ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling.
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele   +13 more
doaj   +1 more source

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2016
The presence of ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1) rearrangements in lung cancers confers sensitivity to ROS kinase inhibitors, including crizotinib. However, they are rare abnormalities (in ∼1% of non-small cell lung carcinomas) that are typically identified by fluorescence in situ hybridization (FISH), and so screening using ...
Viola, P, Maurya, M, Croud, J, Gazdova, J, Suleman, N, Lim, E, Newsom-Davis, T, Plowman, N, Rice, A, Montero, MA, Gonzalez de Castro, D, Popat, S, Nicholson, AG   +12 more
openaire   +3 more sources

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Pan-cancer analysis of ROS1 genomic aberrations

, 2015
The ROS proto-oncogene 1 (ROS1) encodes the ROS1 receptor kinase. ROS1 rearrangements are known to be oncogenic in glioblastoma, non–small-cell lung carcinoma (NSCLC) and cholangiocarcinoma.
王奕丹, Wang, Yidan
core   +1 more source

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

Frontiers in Oncology, 2021
PurposeDespite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially non-small cell lung cancer (NSCLC), the clinical significance of ROS1 de novo mutation has not yet been understood.
Si-Cong Ma, Si-Cong Ma, Hong-Bo Zhu, Jian Wang, Yan-Pei Zhang, Yan-Pei Zhang, Xue-Jun Guo, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Zhong-Yi Dong, Xue Bai   +11 more
doaj   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source